$KYMR
Kymera Therapeutics, Inc.

2024 Q2 Form 10-Q Financial Statement

#000095017024051567 Filed on May 02, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2024 Q1
Revenue $25.65M $10.29M
YoY Change 55.33% 8.67%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $17.37M $14.37M
YoY Change 22.96% 14.4%
% of Gross Profit
Research & Development $59.20M $48.82M
YoY Change 29.36% 15.61%
% of Gross Profit
Depreciation & Amortization $1.900M $1.461M
YoY Change 111.11% 66.21%
% of Gross Profit
Operating Expenses $76.58M $68.12M
YoY Change 27.85% 24.32%
Operating Profit -$50.93M -$57.83M
YoY Change 17.38% 27.59%
Interest Expense $8.863M $9.274M
YoY Change 93.35% 110.87%
% of Operating Profit
Other Income/Expense, Net $8.863M $9.274M
YoY Change 93.35% 110.87%
Pretax Income -$42.06M -$48.56M
YoY Change 8.41% 18.64%
Income Tax
% Of Pretax Income
Net Earnings -$42.06M -$48.56M
YoY Change 8.41% 18.64%
Net Earnings / Revenue -163.98% -472.02%
Basic Earnings Per Share -$0.58 -$0.69
Diluted Earnings Per Share -$0.58 -$0.69
COMMON SHARES
Basic Shares Outstanding 61.36M 61.11M
Diluted Shares Outstanding 73.06M 70.77M

Balance Sheet

Concept 2024 Q2 2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $510.0M $520.5M
YoY Change 38.73% 31.16%
Cash & Equivalents $67.61M $93.51M
Short-Term Investments $442.3M $427.0M
Other Short-Term Assets $13.75M $14.68M
YoY Change 0.32% 29.3%
Inventory
Prepaid Expenses
Receivables $0.00 $0.00
Other Receivables $0.00 $0.00
Total Short-Term Assets $525.4M $537.3M
YoY Change 36.33% 30.54%
LONG-TERM ASSETS
Property, Plant & Equipment $51.74M $49.34M
YoY Change 88.17% 183.02%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $192.4M $224.4M
YoY Change 83.7% 88.54%
Other Assets $1.889M $2.118M
YoY Change -32.58% -32.87%
Total Long-Term Assets $300.6M $331.0M
YoY Change 52.95% 63.57%
TOTAL ASSETS
Total Short-Term Assets $525.4M $537.3M
Total Long-Term Assets $300.6M $331.0M
Total Assets $826.0M $868.3M
YoY Change 41.94% 41.43%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $6.510M $6.812M
YoY Change 73.83% 5.07%
Accrued Expenses $23.78M $16.00M
YoY Change 5.74% -13.54%
Deferred Revenue $19.26M $22.61M
YoY Change -20.75% -29.88%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $992.0K $1.133M
YoY Change -19.42% -15.38%
Total Short-Term Liabilities $62.14M $56.14M
YoY Change 13.81% -9.36%
LONG-TERM LIABILITIES
Long-Term Debt $943.0K $1.156M
YoY Change 23.75% 16.89%
Other Long-Term Liabilities $78.01M $99.76M
YoY Change 33817.83% 41991.14%
Total Long-Term Liabilities $78.95M $100.9M
YoY Change 34227.83% 42478.9%
TOTAL LIABILITIES
Total Short-Term Liabilities $62.14M $56.14M
Total Long-Term Liabilities $78.95M $100.9M
Total Liabilities $141.1M $157.0M
YoY Change -3.7% 3.39%
SHAREHOLDERS EQUITY
Retained Earnings -$621.4M -$579.3M
YoY Change 34.07% 36.4%
Common Stock $1.308B $1.292B
YoY Change 44.96% 45.24%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $684.9M $711.2M
YoY Change
Total Liabilities & Shareholders Equity $826.0M $868.3M
YoY Change 41.94% 41.43%

Cashflow Statement

Concept 2024 Q2 2024 Q1
OPERATING ACTIVITIES
Net Income -$42.06M -$48.56M
YoY Change 8.41% 18.64%
Depreciation, Depletion And Amortization $1.900M $1.461M
YoY Change 111.11% 66.21%
Cash From Operating Activities -$42.94M -$39.59M
YoY Change 21.78% -9.95%
INVESTING ACTIVITIES
Capital Expenditures $4.689M $7.402M
YoY Change -56.45% 84.63%
Acquisitions
YoY Change
Other Investing Activities $20.33M -$323.2M
YoY Change -56.38% -1230.36%
Cash From Investing Activities $15.64M -$330.6M
YoY Change -56.35% -1444.81%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.412M 353.8M
YoY Change 8.2% 30422.52%
NET CHANGE
Cash From Operating Activities -42.94M -39.59M
Cash From Investing Activities 15.64M -330.6M
Cash From Financing Activities 1.412M 353.8M
Net Change In Cash -25.88M -16.44M
YoY Change -1470.87% -9.78%
FREE CASH FLOW
Cash From Operating Activities -$42.94M -$39.59M
Capital Expenditures $4.689M $7.402M
Free Cash Flow -$47.63M -$46.99M
YoY Change 3.48% -2.05%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q1 dei Amendment Flag
AmendmentFlag
false
CY2024Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2024Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2024Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001815442
CY2022Q4 kymr Fair Value Assets Level2 To Level3 Transfers Amount
FairValueAssetsLevel2ToLevel3TransfersAmount
CY2024Q1 us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://fasb.org/us-gaap/2023#RelatedPartyMember
CY2023Q1 us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://fasb.org/us-gaap/2023#RelatedPartyMember
CY2024Q1 kymr Fair Value Assets Level3 To Level2 Transfers Amount
FairValueAssetsLevel3ToLevel2TransfersAmount
0
CY2023Q4 kymr Fair Value Assets Level2 To Level3 Transfers Amount
FairValueAssetsLevel2ToLevel3TransfersAmount
0
CY2024Q1 dei Document Type
DocumentType
10-Q
CY2024Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2024Q1 dei Document Period End Date
DocumentPeriodEndDate
2024-03-31
CY2024Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2024Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2024Q1 dei Entity File Number
EntityFileNumber
001-39460
CY2024Q1 dei Entity Registrant Name
EntityRegistrantName
KYMERA THERAPEUTICS, INC.
CY2024Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2024Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
81-2992166
CY2024Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
500 North Beacon Street
CY2024Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
4th Floor
CY2024Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Watertown
CY2024Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2024Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02472
CY2024Q1 dei City Area Code
CityAreaCode
857
CY2024Q1 dei Local Phone Number
LocalPhoneNumber
285-5300
CY2024Q1 dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
CY2024Q1 dei Trading Symbol
TradingSymbol
KYMR
CY2024Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2024Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2024Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2024Q1 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2024Q1 dei Entity Small Business
EntitySmallBusiness
false
CY2024Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2024Q1 dei Entity Shell Company
EntityShellCompany
false
CY2024Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
61358262
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
93510000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
109966000
CY2024Q1 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
427034000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
264915000
CY2024Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
0
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
15000000
CY2024Q1 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
2030000
CY2023Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
3762000
CY2024Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
14679000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
11674000
CY2024Q1 us-gaap Assets Current
AssetsCurrent
537253000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
405317000
CY2024Q1 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
224390000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
61434000
CY2024Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
49336000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
48134000
CY2024Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
49329000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
52945000
CY2024Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2118000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2118000
CY2024Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
5825000
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
5811000
CY2024Q1 us-gaap Assets
Assets
868251000
CY2023Q4 us-gaap Assets
Assets
575759000
CY2024Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
6812000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
7075000
CY2024Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
15997000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
33864000
CY2024Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
22613000
CY2023Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
37883000
CY2024Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
8757000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
5068000
CY2024Q1 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
1133000
CY2023Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
1277000
CY2024Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
824000
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
524000
CY2024Q1 us-gaap Liabilities Current
LiabilitiesCurrent
56136000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
85691000
CY2024Q1 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
23781000
CY2023Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
16768000
CY2024Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
75975000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
77028000
CY2024Q1 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
1156000
CY2023Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
1301000
CY2024Q1 us-gaap Liabilities
Liabilities
157048000
CY2023Q4 us-gaap Liabilities
Liabilities
180788000
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
61353146
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
61353146
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
55585305
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
55585305
CY2024Q1 us-gaap Common Stock Value
CommonStockValue
6000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
6000
CY2024Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1292283000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
926269000
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-579309000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-530752000
CY2024Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1777000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-552000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
711203000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
394971000
CY2024Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
868251000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
575759000
CY2024Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
10287000
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
9466000
CY2024Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
48819000
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
42227000
CY2024Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
14374000
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12565000
CY2024Q1 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
4925000
CY2023Q1 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2024Q1 us-gaap Operating Expenses
OperatingExpenses
68118000
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
54792000
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-57831000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-45326000
CY2024Q1 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
9343000
CY2023Q1 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
4453000
CY2024Q1 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
69000
CY2023Q1 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
55000
CY2024Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
9274000
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
4398000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-48557000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-40928000
CY2024Q1 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-1225000
CY2023Q1 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
1911000
CY2024Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-49782000
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-39017000
CY2024Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-48557000
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-40928000
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.69
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.69
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.7
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.7
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
70770320
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
70770320
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
58187038
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
58187038
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
490151000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1486000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
9385000
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
1911000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-40928000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
462005000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
394971000
CY2024Q1 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
14900000
CY2024Q1 kymr Issuance Of Common Stock At Private Placement Net Of Issuance Cost
IssuanceOfCommonStockAtPrivatePlacementNetOfIssuanceCost
301373000
CY2024Q1 kymr Proceeds From Issuance Of Common Stock Under Atm
ProceedsFromIssuanceOfCommonStockUnderATM
1200000
CY2024Q1 kymr Issuance Of Common Stock Under Atm Net Of Issuance Costs Amount
IssuanceOfCommonStockUnderATMNetOfIssuanceCostsAmount
48740000
CY2024Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3933000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
11968000
CY2024Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-1225000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-48557000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
711203000
CY2024Q1 us-gaap Profit Loss
ProfitLoss
-48557000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-40928000
CY2024Q1 us-gaap Share Based Compensation
ShareBasedCompensation
11968000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
9385000
CY2024Q1 us-gaap Asset Impairment Charges
AssetImpairmentCharges
4925000
CY2023Q1 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2024Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1461000
CY2023Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
879000
CY2024Q1 kymr Premiums And Discounts On Available For Sale Marketable Securities
PremiumsAndDiscountsOnAvailableForSaleMarketableSecurities
-3072000
CY2023Q1 kymr Premiums And Discounts On Available For Sale Marketable Securities
PremiumsAndDiscountsOnAvailableForSaleMarketableSecurities
-1326000
CY2024Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3005000
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1641000
CY2024Q1 us-gaap Increase Decrease In Due From Related Parties
IncreaseDecreaseInDueFromRelatedParties
-15000000
CY2023Q1 us-gaap Increase Decrease In Due From Related Parties
IncreaseDecreaseInDueFromRelatedParties
0
CY2024Q1 kymr Increase Decrease In Contract With Customer Asset Related Parties
IncreaseDecreaseInContractWithCustomerAssetRelatedParties
-1732000
CY2023Q1 kymr Increase Decrease In Contract With Customer Asset Related Parties
IncreaseDecreaseInContractWithCustomerAssetRelatedParties
783000
CY2024Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
75000
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2217000
CY2024Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-15394000
CY2023Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-10037000
CY2024Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-8257000
CY2023Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-6145000
CY2024Q1 kymr Increase Decrease In Operating Lease Right Of Use Assets
IncreaseDecreaseInOperatingLeaseRightOfUseAssets
-619000
CY2023Q1 kymr Increase Decrease In Operating Lease Right Of Use Assets
IncreaseDecreaseInOperatingLeaseRightOfUseAssets
-1138000
CY2024Q1 kymr Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
2636000
CY2023Q1 kymr Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
2915000
CY2024Q1 us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
-278000
CY2023Q1 us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
-358000
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-39591000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-43968000
CY2024Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
7402000
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4009000
CY2024Q1 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
422704000
CY2023Q1 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
61835000
CY2024Q1 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
99499000
CY2023Q1 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
90428000
CY2024Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-330607000
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
24584000
CY2024Q1 kymr Issuance Of Common Stock And Accompanying Pre Funded Warrants At Private Placement Net Of Issuance Costs
IssuanceOfCommonStockAndAccompanyingPreFundedWarrantsAtPrivatePlacementNetOfIssuanceCosts
301373000
CY2023Q1 kymr Issuance Of Common Stock And Accompanying Pre Funded Warrants At Private Placement Net Of Issuance Costs
IssuanceOfCommonStockAndAccompanyingPreFundedWarrantsAtPrivatePlacementNetOfIssuanceCosts
0
CY2024Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
48740000
CY2023Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0
CY2024Q1 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
3933000
CY2023Q1 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
1486000
CY2024Q1 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
290000
CY2023Q1 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
327000
CY2024Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
353756000
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1159000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-16442000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-18225000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
115777000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
74524000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
99335000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
56299000
CY2024Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
CY2023Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
48833000
CY2024Q1 us-gaap Interest Paid Net
InterestPaidNet
49000
CY2023Q1 us-gaap Interest Paid Net
InterestPaidNet
52000
CY2024Q1 kymr Property And Equipment Purchases Included In Accounts Payable And Accrued Expenses
PropertyAndEquipmentPurchasesIncludedInAccountsPayableAndAccruedExpenses
1205000
CY2023Q1 kymr Property And Equipment Purchases Included In Accounts Payable And Accrued Expenses
PropertyAndEquipmentPurchasesIncludedInAccountsPayableAndAccruedExpenses
1100000
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
93510000
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
50152000
CY2024Q1 us-gaap Restricted Cash
RestrictedCash
5825000
CY2023Q1 us-gaap Restricted Cash
RestrictedCash
6147000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
99335000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
56299000
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-579300000
CY2024Q1 us-gaap Investments And Cash
InvestmentsAndCash
744900000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
10440000
CY2024Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
49336000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
48134000
CY2024Q1 us-gaap Depreciation
Depreciation
1500000
CY2024Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
653186000
CY2024Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
22000
CY2024Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1784000
CY2024Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
651424000
CY2023Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
326907000
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
166000
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
724000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
326349000
CY2024Q1 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
113
CY2024Q1 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
467400000
CY2023Q1 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
109
CY2023Q1 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
229700000
CY2024Q1 kymr Debt Securities Available For Sale Decline In Market Value For Unrealized Loss Position Number Of Securities
DebtSecuritiesAvailableForSaleDeclineInMarketValueForUnrealizedLossPositionNumberOfSecurities
39
CY2024Q1 kymr Debt Securities Available For Sale Continuous Unrealized Loss Position Greater Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionGreaterThan12Months
81500000
CY2023Q1 kymr Debt Securities Available For Sale Decline In Market Value For Unrealized Loss Position Number Of Securities
DebtSecuritiesAvailableForSaleDeclineInMarketValueForUnrealizedLossPositionNumberOfSecurities
16
CY2023Q1 kymr Debt Securities Available For Sale Continuous Unrealized Loss Position Greater Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionGreaterThan12Months
36600000
CY2024Q1 kymr Debt Securities Available For Sale Contractual Maturity Of Less Than12 Months Number Of Securities
DebtSecuritiesAvailableForSaleContractualMaturityOfLessThan12MonthsNumberOfSecurities
140
CY2024Q1 kymr Fair Value Of Available For Sale Debt Securities Contractual Maturity Of Less Than Twelve Months
FairValueOfAvailableForSaleDebtSecuritiesContractualMaturityOfLessThanTwelveMonths
427000000
CY2024Q1 kymr Debt Securities Available For Sale Contractual Maturity Of12 Months Or Longer Number Of Securities
DebtSecuritiesAvailableForSaleContractualMaturityOf12MonthsOrLongerNumberOfSecurities
61
CY2024Q1 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
224400000
CY2023Q1 kymr Debt Securities Available For Sale Contractual Maturity Of Less Than12 Months Number Of Securities
DebtSecuritiesAvailableForSaleContractualMaturityOfLessThan12MonthsNumberOfSecurities
124
CY2023Q1 kymr Fair Value Of Available For Sale Debt Securities Contractual Maturity Of Less Than Twelve Months
FairValueOfAvailableForSaleDebtSecuritiesContractualMaturityOfLessThanTwelveMonths
264900000
CY2023Q1 kymr Debt Securities Available For Sale Contractual Maturity Of12 Months Or Longer Number Of Securities
DebtSecuritiesAvailableForSaleContractualMaturityOf12MonthsOrLongerNumberOfSecurities
27
CY2023Q1 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
61400000
CY2024Q1 kymr Available For Sale Securities Credit Losses
AvailableForSaleSecuritiesCreditLosses
0
CY2023Q4 kymr Available For Sale Securities Credit Losses
AvailableForSaleSecuritiesCreditLosses
0
CY2024Q1 kymr Cost Reimbursement Payment Received
CostReimbursementPaymentReceived
3800000
CY2024Q1 us-gaap Unbilled Contracts Receivable
UnbilledContractsReceivable
2000000
CY2024Q1 kymr Remaining Research Term Of Collaboration
RemainingResearchTermOfCollaboration
P2Y9M18D
CY2024Q1 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
42600000
CY2024Q1 us-gaap Deferred Revenue Revenue Recognized1
DeferredRevenueRevenueRecognized1
55000000
CY2024Q1 us-gaap Deferred Revenue
DeferredRevenue
12400000
CY2023Q4 us-gaap Contract With Customer Receivable After Allowance For Credit Loss
ContractWithCustomerReceivableAfterAllowanceForCreditLoss
18762000
CY2024Q1 kymr Contract With Customer Asset Net Additions
ContractWithCustomerAssetNetAdditions
5792000
CY2024Q1 kymr Contract With Customer Asset Net Deductions
ContractWithCustomerAssetNetDeductions
22524000
CY2024Q1 us-gaap Contract With Customer Receivable After Allowance For Credit Loss
ContractWithCustomerReceivableAfterAllowanceForCreditLoss
2030000
CY2023Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
54651000
CY2024Q1 kymr Contract With Customer Liability Additions
ContractWithCustomerLiabilityAdditions
2030000
CY2024Q1 kymr Contract With Customer Liability Deductions
ContractWithCustomerLiabilityDeductions
-10287000
CY2024Q1 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
46394000
CY2024Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
59872000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
58574000
CY2024Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
10536000
CY2023Q1 us-gaap Depreciation
Depreciation
900000
CY2024Q1 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
400000
CY2023Q1 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
400000
CY2024Q1 us-gaap Impairment Charge On Reclassified Assets
ImpairmentChargeOnReclassifiedAssets
4900000
CY2024Q1 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.0817
CY2023Q1 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.0852
CY2024Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
2489000
CY2023Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
2521000
CY2024Q1 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
414000
CY2023Q1 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
369000
CY2024Q1 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
49000
CY2023Q1 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
52000
CY2024Q1 us-gaap Variable Lease Cost
VariableLeaseCost
1204000
CY2023Q1 us-gaap Variable Lease Cost
VariableLeaseCost
220000
CY2024Q1 us-gaap Lease Cost
LeaseCost
4156000
CY2023Q1 us-gaap Lease Cost
LeaseCost
3162000
CY2024Q1 kymr Operating Lease Payments Proceeds
OperatingLeasePaymentsProceeds
670000
CY2023Q1 kymr Operating Lease Payments Proceeds
OperatingLeasePaymentsProceeds
651000
CY2024Q1 us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
383000
CY2023Q1 us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
327000
CY2024Q1 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
49000
CY2023Q1 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
52000
CY2024Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P10Y2M26D
CY2023Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P10Y9M
CY2024Q1 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P2Y4M9D
CY2023Q1 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P2Y3M29D
CY2024Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0874
CY2023Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0887
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
6270000
CY2024Q1 us-gaap Finance Lease Liability Payments Remainder Of Fiscal Year
FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
919000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
12074000
CY2024Q1 us-gaap Finance Lease Liability Payments Due Next Twelve Months
FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
915000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
12436000
CY2024Q1 us-gaap Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
566000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
12809000
CY2024Q1 us-gaap Finance Lease Liability Payments Due Year Three
FinanceLeaseLiabilityPaymentsDueYearThree
108000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
13193000
CY2024Q1 us-gaap Finance Lease Liability Payments Due Year Four
FinanceLeaseLiabilityPaymentsDueYearFour
0
CY2024Q1 kymr Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
74424000
CY2024Q1 kymr Finance Lease Liability Payments Due After Year Four
FinanceLeaseLiabilityPaymentsDueAfterYearFour
0
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
131206000
CY2024Q1 us-gaap Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
2508000
CY2024Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
46474000
CY2024Q1 us-gaap Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
219000
CY2024Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
84732000
CY2024Q1 us-gaap Finance Lease Liability
FinanceLeaseLiability
2289000
CY2024Q1 kymr Undiscounted Future Lease Payments
UndiscountedFutureLeasePayments
2600000
CY2024Q1 kymr Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
8021000
CY2023Q4 kymr Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
15099000
CY2024Q1 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
4574000
CY2023Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
11227000
CY2024Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2271000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
3854000
CY2024Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1131000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
3684000
CY2024Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
15997000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
33864000
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y9M14D
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y9M25D
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.65
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.62
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0413
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0414
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2024Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
11968000
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9385000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-48557000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-40928000
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
70770320
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
70770320
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
58187038
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
58187038
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.69
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.69
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.7
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.7
CY2024Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10602152
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8744452
CY2024Q1 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q1 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q1 ecd Trd Arr Ind Name
TrdArrIndName
Joanna Horobin
CY2024Q1 ecd Trd Arr Ind Title
TrdArrIndTitle
Director
CY2024Q1 ecd Trd Arr Adoption Date
TrdArrAdoptionDate
March 8, 2024
CY2024Q1 ecd Trd Arr Termination Date
TrdArrTerminationDate
July 1, 2025
CY2024Q1 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q1 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0000950170-24-051567-index-headers.html Edgar Link pending
0000950170-24-051567-index.html Edgar Link pending
0000950170-24-051567.txt Edgar Link pending
0000950170-24-051567-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
kymr-20240331.htm Edgar Link pending
kymr-20240331.xsd Edgar Link pending
kymr-ex10_1.htm Edgar Link pending
kymr-ex31_1.htm Edgar Link pending
kymr-ex31_2.htm Edgar Link pending
kymr-ex32_1.htm Edgar Link pending
kymr-ex32_2.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
kymr-20240331_htm.xml Edgar Link completed
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending